OncoMatch/Clinical Trials/NCT05554302
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Is NCT05554302 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 18F-Fluciclovine for brain metastases.
Treatment: 18F-Fluciclovine — This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Metastatic disease required
Radiographic diagnosis of brain metastasis
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: whole-brain radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Miami Cancer Institute at Baptist Health South Florida · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify